RALEIGH, NC--German life sciences company Bayer has signed a contract with Paradigm Genetics here under which they will collaborate in a search for screening targets leading to the development of new herbicides. For contributing its expertise in bioinformatics, gene function identification, and assay development, Paradigm will receive up to $40 million, including milestone payments. Genes identified as being responsible for new targets will be subjected to high-throughput screening.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.